(Dimethylamino)acetaldehyde Diethyl Acetal CAS 3616-56-6 Purity >99.0% (GC) Afatinib Dimaleate Intermediate Factory

(Dimethylamino)acetaldehyde Diethyl Acetal (CAS: 3616-56-6) is used as pharmaceutical intermediates. (Dimethylamino)acetaldehyde Diethyl Acetal can be used in the synthesis of Afatinib Dimaleate (CAS: 850140-73-7), Sumatriptan (CAS: 103628-46-2). Afatinib (trade name Gilotrif in the US and Giotrif in Europe, previously Tomtovok and Tovok) is a drug approved in United States, Europe, Taiwan, Mexico, Chile and Japan as well as other countries for the first-line treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim. Afatinib acts as an irreversible covalent inhibitor of thereceptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (HER2). Sumatriptan was the first triptan approved (1991) for theacute treatment of migraine headaches. It has the lowestoral bioavailability among all triptans because of its lowlipophilicity. The availability of many different dosageforms (i.e., an oral tablet, a SC injection, a nasal spray formulation,and a suppository) allows the flexibility of tailoringtherapy to the needs of the individual patients, thusmaking sumatriptans a very useful drug for an acute treatmentof migraine headaches. Sumatriptan also has a very fastonset of action via SC injection or nasal spray administration.